Polydrug gets warning letter: Filth, goggles in APIs too much for FDA

FDA headquarters
FDA headquarters

It is one thing if customers complain about finding impurities in an API from a supplier, but customers of India’s Polydrug Laboratories found a lot more than that. One reported particles and hairs, while another found an insect and dirt. But then there was the scoop that one customer reported, while in another API, there were goggles. And the FDA says Polydrug never bothered to check out any of these problems.  

The uninvestigated complaints are lined out in a warning letter the FDA recently sent to the Indian drugmaker about its plant in Maharashtra, India, and which it posted to its website last week. In the warning the FDA noted that its investigator found a torn record in a warehouse that outlined 17 complaints of this nature, only two of which were listed in its official reports. It doesn’t matter that not all of those complaints were from U.S. customers, the FDA said. The drugmaker uses the same equipment and processes for its U.S. production and the fact that there were uninvestigated complaints about “APIs that were either sub-potent or contained filth” were more than enough indication for the agency that Polydrug has serious problems.

There were also big issues with data integrity, a common problem with Indian API makers. For example, a  manager demonstrated for the investigator how results on an already finalized clinical outcomes assessment could be manipulated after it had been evaluated by the quality unit, the warning letter said.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Among the responses the FDA expects before it will allow Polydrug to sell any more APIs in the U.S. is a summary of investigations into all complaints the company has received since 2012 to determine the root cause of the problem and how it plans to address them.

The difficulties for Polydrug have been building for a year. In June 2015, European regulators banned products from three of its plants because the drug manufacturer was ignoring customer complaints. Health Canada followed suit a couple of weeks later, and then in September the FDA banned products from the Polydrug plant in Maharashtra.

- read the warning letter 

Related Article: 
India's Polydrug Labs criticized for contaminated APIs

Suggested Articles

Novartis' AveXis will use Catalent for some manufacturing of its newly approved gene therapy Zolgensma and more manufacturing news of note.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps. 

Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.